Ar­alez fi­nal­ly gets an FDA OK for its car­dio drug Yosprala, starts hir­ing sales reps

The third time proved the charm for Ar­alez Phar­ma­ceu­ti­cals. Af­ter two years of back and forth with the FDA over a se­ri­ous man­u­fac­tur­ing sna­fu, the agency has fi­nal­ly giv­en its thumbs up to the biotech’s car­dio drug Yosprala.

The ap­proval clears the way for the Cana­di­an com­pa­ny to add 85 sales reps to its com­mer­cial­iza­tion arm. Yosprala is ap­proved for “pa­tients who re­quire as­pirin for sec­ondary pre­ven­tion of car­dio­vas­cu­lar and cere­brovas­cu­lar events and who are at risk of de­vel­op­ing as­pirin as­so­ci­at­ed gas­tric ul­cers.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.